Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 697947109 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
First Light Asset Management, LLC
13G/A
Amendment 1
|
5.3% |
8/14/2026
Event 6/30/2026
|
|
| First Light Asset Management, LLC | 5.3% | ||
| Mathew P. Arens | 5.3% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 4
|
4.7% |
8/14/2026
Event 6/30/2026
|
|
| Biotechnology Value Fund L P | 2.5% | ||
| BVF I GP LLC | 2.5% | ||
| Biotechnology Value Fund II LP | 1.9% | ||
| BVF II GP LLC | 1.9% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 4.3% | ||
| BVF Partners L P/IL | 4.7% | ||
| BVF Inc/IL | 4.7% | ||
| Lampert Mark N | 4.7% | ||
| Prudential Financial Inc 13G | 6.7% |
8/10/2026
Event 6/30/2026
|
|
| Jennison Associates LLC 13G | 6.7% |
8/3/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G | 5.7% |
7/29/2026
Event 6/30/2026
|
|
|
First Light Asset Management, LLC
13G
|
7.5% |
2/17/2026
Event 12/31/2025
|
|
| First Light Asset Management, LLC | 7.5% | ||
| Mathew P. Arens | 7.5% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 3
|
7.1% |
2/17/2026
Event 12/31/2025
|
|
| Biotechnology Value Fund L P | 3.8% | ||
| BVF I GP LLC | 3.8% | ||
| Biotechnology Value Fund II LP | 2.8% | ||
| BVF II GP LLC | 2.8% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 6.6% | ||
| BVF Partners L P/IL | 7.1% | ||
| BVF Inc/IL | 7.1% | ||
| Lampert Mark N | 7.1% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 3
|
6.0% |
2/13/2026
Event 12/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 6.0% | ||
| FHMLSP, L.P. | 6.0% | ||
| FHMLSP, L.L.C. | 6.0% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0.1% | ||
| FHMLS XI, L.P. | 0.1% | ||
| FHMLS XI, L.L.C. | 0.1% | ||
| Frazier Life Sciences XII, L.P. | 0% | ||
| FHMLS XII, L.P. | 0% | ||
| FHMLS XII, L.L.C. | 0% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
| Biotechnology Value Fund L P | 5.4% | ||
| BVF I GP LLC | 5.4% | ||
| Biotechnology Value Fund II LP | 4.0% | ||
| BVF II GP LLC | 4.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||
| BVF Partners OS Ltd. | 0.5% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Suvretta Capital Management, LLC
13G/A
Amendment 1
|
7.4% |
11/13/2025
Event 9/30/2025
|
|
| Suvretta Capital Management, LLC | 7.4% | ||
| Averill Master Fund, Ltd. | 6.5% | ||
| Aaron Cowen | 7.4% | ||
|
Samsara BioCapital, L.P.
13G/A
Amendment 1
|
3.1% |
8/14/2025
Event 6/30/2025
|
|
| Samsara BioCapital, L.P. | 3.1% | ||
| Samsara BioCapital GP, LLC | 3.1% | ||
| Srinivas Akkaraju | 3.1% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
4.9% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.9% | ||
| FHMLSP, L.P. | 4.9% | ||
| FHMLSP, L.L.C. | 4.9% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||
| FHMLSP Overage, L.P. | 1.5% | ||
| FHMLSP Overage, L.L.C. | 1.5% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0.1% | ||
| FHMLS XI, L.P. | 0.1% | ||
| FHMLS XI, L.L.C. | 0.1% | ||
| Frazier Life Sciences XII, L.P. | 0% | ||
| FHMLS XII, L.P. | 0% | ||
| FHMLS XII, L.L.C. | 0% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
6.3% |
5/15/2025
Event 3/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.8% | ||
| FHMLSP, L.P. | 4.8% | ||
| FHMLSP, L.L.C. | 4.8% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.4% | ||
| FHMLSP Overage, L.P. | 1.4% | ||
| FHMLSP Overage, L.L.C. | 1.4% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 6.3% | ||
| Patrick J. Heron | 6.3% | ||
| Albert Cha | 6.2% | ||
| James Brush | 6.2% | ||
| Daniel Estes | 0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
5.1% |
1/8/2025
Event 12/13/2024
|
|
| Frazier Life Sciences Public Fund, L.P. | 3.9% | ||
| FHMLSP, L.P. | 3.9% | ||
| FHMLSP, L.L.C. | 3.9% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||
| FHMLSP Overage, L.P. | 1.2% | ||
| FHMLSP Overage, L.L.C. | 1.2% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 5.1% | ||
| Patrick J. Heron | 5.1% | ||
| Albert Cha | 5.1% | ||
| James Brush | 5.1% | ||
| Daniel Estes | 0% | ||
|
Kaupinen Wes
13D
|
14.6% |
12/20/2024
Event 12/13/2024
|
|
| Kaupinen Wes | 14.6% | ||
| Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019 | 6.9% | ||
| Christine L. Kaupinen | 13.9% | ||
| Christine L. Kaupinen 2019 Irrevocable Trust dated February 28, 2019 | 6.9% | ||
| Michael Christopher | 6.9% | ||
|
Samsara BioCapital, L.P.
13G
|
6.1% |
12/20/2024
Event 12/13/2024
|
|
| Samsara BioCapital, L.P. | 6.1% | ||
| Samsara BioCapital GP, LLC | 6.1% | ||
| Srinivas Akkaraju | 6.1% | ||
|
Suvretta Capital Management, LLC
13G
|
8.6% |
12/20/2024
Event 12/13/2024
|
|
| Suvretta Capital Management, LLC | 8.6% | ||
| Averill Master Fund, Ltd. | 8.6% | ||
| Aaron Cowen | 8.6% | ||
|
Dellora Investments LP
13G/A
Amendment 2
|
1.3% |
12/17/2024
Event 12/13/2024
|
|
| Dellora Investments Master Fund LP | 1.1% | ||
| Dellora Investments LP | 1.3% | ||
| Kevin Pyun | 1.3% |